This is the authors' abstract. We don't add key points for this paper.
Preclinical evidence indicates that repeated treatment with antidepressant drugs (serotonin [5-HT] reuptake or monoamine oxidase [MAO] inhibitors) potentiates the ascending brain serotonergic pathways.1,2Also, clinical data show that the inhibition of 5-HT synthesis results in a marked worsening of patients recovering from depression who are treated with these drugs.3-5These findings suggest that the antidepressant effects of uptake and MAO inhibitors emerge when serotonergic activity increases. Using intracerebral microdialysis in the awake, freely moving rat, a single treatment with 5-HT uptake blockers, such as clomipramine6or fluvoxamine,7was reported to cause little or no increase of 5-HT concentration in frontal cortex at doses comparable with or higher than those used clinically. In contrast, extracellular 5-HT concentration is dramatically augmented by the same doses in the vicinity of cell bodies of serotonergic neurons, in the midbrain raphe nuclei, a preferential increase also observed after a single treatment
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Francesc Artigas (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: